A histone deacetylases 1 and 2 inhibitor is being developed by researchers from the University of Utah's Huntsman Cancer Institute for the treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia. A study in the journal Leukemia found the drug was associated with 50% to 70% leukemia load reductions in tests of mice.
Drug candidate shows potential against Philadelphia chromosome leukemia
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.